Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$25.17 USD
-1.18 (-4.48%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $25.16 -0.01 (-0.04%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
AKRO 25.17 -1.18(-4.48%)
Will AKRO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AKRO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AKRO
Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues
Waters (WAT) Q2 Earnings & Sales Beat Estimates, Fall Y/Y
AKRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues
Philips (PHG) Q2 Earnings Rise, Revenues Fall Year Over Year
Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade
Other News for AKRO
venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies
Class Action Lawsuit against Akero Therapeutics, Inc. (NASDAQ:AKRO)
Akero Therapeutics Shares Cross Above 200 DMA
Optimistic Buy Rating for Akero Therapeutics Amidst Promising Efruxifermin (EFX) Developments
Wolfe Research starts Akero at outperform, cites MASH drug prospects